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BACKGROUND: Subclinical hypothyroidism has been associated with heart failure, but only small trials
assessed whether treatment with levothyroxine has an impact on cardiac function.
METHODS: In a randomized, double-blind, placebo-controlled, trial nested within the TRUST trial, Swiss
participants ages ≥65 years with subclinical hypothyroidism (thyroid-stimulating hormone [TSH] 4.60-
19.99 mIU/L; free thyroxine level within reference range) were randomized to levothyroxine (starting
dose of 50 mg daily) to achieve TSH normalization or placebo. The primary outcomes were the left ven-
tricular ejection fraction for systolic function and the ratio between mitral peak velocity of early filling to
early diastolic mitral annular velocity (E/e0 ratio) for diastolic function. Secondary outcomes included e0
lateral/septal, left atrial volume index, and systolic pulmonary artery pressure.
RESULTS: A total of 185 participants (mean age 74.1 years, 47% women) underwent echocardiography at
the end of the trial. After a median treatment duration of 18.4 months, the mean TSH decreased from
6.35 mIU/L to 3.55 mIU/L with levothyroxine (n = 96), and it remained elevated at 5.29 mIU/L with pla-
cebo (n = 89). The adjusted between-group difference was not significant for the mean left ventricular
ejection fraction (62.7% vs 62.5%, difference = 0.4%, 95% confidence interval 1.8% to 2.5%, P = 0.72)
and the E/e0 ratio (10.6 vs 10.1, difference 0.4, 95% confidence interval 0.7 to 1.4, P = 0.47). No differ-
ences were found for the secondary diastolic function parameters or for interaction according to sex, base-
line TSH, preexisting heart failure, and treatment duration (P value >0.05).
CONCLUSION: Systolic and diastolic heart function did not differ after treatment with levothyroxine com-
pared with placebo in older adults with mild subclinical hypothyroidism.
 2020 Elsevier Inc. All rights reserved.  The American Journal of Medicine (2020) 133:848−856
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Subclinical hypothyroidism, defined as thyroid-stimulating
hormone (TSH) above the reference range with free thyrox-
ine (FT4) levels within the defined reference range, is a
common condition affecting up to 10%-20% of persons
older than 65 years of age.1 An individual participant data
meta-analysis of large prospective cohorts showed anCLINICAL SIGNIFICANCE
 In this double-blind randomized pla-
cebo-controlled trial of 185 partici-
pants older than 65 years of age with
subclinical hypothyroidism, cardiac
function did not differ with a treat-
ment of levothyroxine after a median
follow-up of 18.4 months.
 The mean left ventricular ejection frac-
tion was similar in both arms, for sys-
tolic function, and no significant
differences were found for the ratio
between mitral peak velocity of early
filling to early diastolic mitral annular
velocity for diastolic function.increased risk of heart failure events
for both subclinical hypothyroidism
and hyperthyroidism compared
with euthyroidism,2 and another
large populational study pointed out
an increased risk of heart failure in
subclinical hyperthyroidism only.3
In the Cardiovascular Health Study,
participants with TSH ≥10mIU/L
had a greater risk of heart failure
compared to individuals with
euthyroidism.4 Baseline mitral peak
velocity of early filling (E), an echo
parameter of diastolic dysfunction,
was greater in participants with
TSH ≥10 mIU/l compared to partic-
ipants with euthyroidism.4
The TRUST trial (“Multi-Modal
Effects of Thyroid Replacement for
Untreated Older Adults with Sub-clinical Hypothyroidism”), the largest available multicenter
randomized controlled trial (RCT) comparing levothyroxine
to placebo in older individuals with subclinical hypothyroid-
ism, was not powered for clinical cardiovascular outcomes.5
In this context E echocardiographic endpoints of cardiac
function are relevant to evaluate the impact of treating sub-
clinical hypothyroidism.6 Several small interventional stud-
ies suggested a potential improvement of systolic and
diastolic function with the treatment of subclinical hypothy-
roidism.1 However, these trials had limitations (ie, small
sample sizes [the largest included only 30 participants], a
higher risk of overestimation or underestimation of treatment
effects associated with small, underpowered trials, or non-
controlled study designs).7-11 Therefore, we aimed to assess
the effect of thyroid hormone therapy on cardiac function in
older adults with subclinical hypothyroidism and hypothe-
sized that thyroid hormone therapy would preserve cardiac
function.METHODS
This trial was registered on ClinicalTrials.gov, number
NCT02832960, as a nested study within the TRUST trial
(ClinicalTrials.gov, number NCT01660126), that included
TRUST participants included at the 2 Swiss study centers
(Inselspital, Bern University Hospital, and Centre Hospitalier
Universitaire Vaudois, Lausanne University Hospital). The
protocol was approved by the local institutional review boards,
and written informed consent obtained from all participants.The TRUST was a 2-arm, parallel, placebo-controlled, dou-
ble-blind, superiority, multicenter, randomized clinical
trial.5 A detailed description of the design and main results
of the TRUST trial have been published previously.5 The
inclusion criteria were an age of 65 years or older and per-
sistent subclinical hypothyroidism, defined as an elevatedthyrotropin level (4.60-19.99 mIU/
L) that was measured on at least 2
occasions that were 3 months to
3 years apart, with the FT4 level
within the reference range. The rele-
vant exclusion criteria for this anal-
ysis were an acute coronary
syndrome (including myocardial
infarction or unstable angina)
within the previous 4 weeks and
severe heart failure, defined as New
York Heart Association stage IV.
Using central web-based computed-
generated randomly permuted
blocks, participants were allocated
in a 1:1 ratio and stratified accord-
ing to sex and treatment starting
dose. The intervention consisted of
levothyroxine with a starting dose
of 50 mg daily, or 25 mg for partici-pants with a body weight of <50 kg or with a history of cor-
onary heart disease. The medication was dose-titrated every
6-8 weeks to achieve a TSH level within the reference range
(0.40-4.59 mIU/L).12 The following algorithm was used: 1)
TSH <0.40 mIU/L meant levothyroxine dose reduced to
25 mg in those starting on 50 mg and replaced with placebo
in those starting on 25 mg; if TSH remained <0.40 mIU/L
after 4-6weeks, the patient was withdrawn from randomized
treatment; 2) TSH 0.40-4.59 mIU/L meant no change to the
levothyroxine dose; patient to be reviewed at 12 months;
and 3) TSH ≥4.60 mIU/L meant additional 25 mg levothyr-
oxine. A mock titration was performed in the placebo group
using an adaptive schedule, in which the data center allo-
cated (by computer algorithm) the same proportion of
patients on placebo to dose adjustment (up or down) as
required in the levothyroxine group (followed by check of
TSH at 6-8 weeks). The participants, investigators, and
treating physicians remained blinded to the results of TSH
measurements and for treatment allocation.Outcomes
We performed an echocardiography at the final visit of the
Swiss participants included in the TRUST trial. The pri-
mary outcome was the ratio (E/e0 ratio) between mitral
peak velocity of early filling (E) to early diastolic mitral
annular velocity (e0) for diastolic function and left ventricu-
lar ejection fraction for systolic function, using the biplane
Simpson rule.6,13 The E/e0 ratio was validated as a strong
predictor of cardiac events in high-risk patients.14 We used
850 The American Journal of Medicine, Vol 133, No 7, July 2020the same approach that previous trials have by comparing
imaging outcomes between treatment groups at the end of
the trial.15,16 Secondary measurements of diastolic function
were: 1) Doppler-derived transmitral inflow patterns (E and
A peak velocity, E/A ratio, E velocity deceleration time,
ratio of transmitral E velocity to tissue Doppler-derived
early diastolic velocity of the mitral annulus, deceleration
time), 2) left atrial volume index using the Biplane Area-
Length Methods, and 3) tricuspid regurgitation velocity.13
To define the presence of diastolic dysfunction in patients
with normal left ventricular ejection fraction, the algorithm
for the diagnosis of diastolic dysfunction was based on: 1)
average E/e0 >14, 2) septal e0 velocity <7 cm/s or lateral e0
velocity <10 cm/s, 3) tricuspid regurgitation velocity
>2.8 m/s, and 4) left atrial volume index > 34mL/m2.13 Par-
ticipants were classified as 1) having diastolic dysfunction
if >2 positive criteria, 2) having indeterminate function if 2
positive criteria, and 3) having normal diastolic function if
<2 positive criteria.13 Additional secondary measurements
comprised systolic pulmonary pressure and longitudinal
global strain.17 The standard acquisition protocol for trans-
thoracic echocardiography was performed by certified oper-
ators.6 The definition of outcome was prespecified before
the acquisition and the plausibility of entered values was
checked by a certified cardiologist (BG).Statistical Analysis
The primary analysis was conducted according to a modified
intention-to-treat principle on a population of participants ran-
domized with echocardiography data.5 We compared the out-
comes between groups with adjustment for variables (sex,
starting dose of levothyroxine, study center, and time to visit),Figure Study flowchart. Home visit indicates participan
the final study visit at home, where it was not possible to pusing multivariable linear regression. Prespecified subgroup
analyses were performed according to sex, TSH levels, preex-
isting cardiovascular disease or heart failure, and use of anti-
hypertensive medication. We also compared the difference in
cardiovascular risk factors, medications and biomarkers (N-
terminal pro b-type natriuretic peptide [NT-proBNP]) between
treatment groups at follow-up at 12 months using multivari-
able linear regression adjusting for the baseline value. Finally,
we examined whether the missing of the primary endpoints
were different in both arms.Power Calculation
With 185 participants with echocardiography, we had a sta-
tistical power of 92% to detect a between-group difference
of the mean of E/e0 ratio and left ventricular ejection frac-
tion of 0.5 standard deviation (SD) units with an alpha = 0.05
(2-sided).14 Our sample size was able to detect differences
of 5% in left ventricular ejection fraction (considering 10%
as a SD) and 1.25 in E/e0 ratio (considering 2.5 as a SD).
All analyses were performed using Stata statistical software
(Version 14, StataCorp LP, College Station, Tex).RESULTS
Studied Population
Figure depicts the study flowchart. Participants were
enrolled from April 2013 through December 2015. In total,
603 participants were screened, and 217 were randomized
to the intervention group (n = 109) or the control group
(n = 108). Thirteen (12%) participants in the intervention
group and 19 (18%) in the control group did not have echo-
cardiography. Four participants in the intervention groupts that requested, usually for mobility issues, to do
erform an echocardiography.
Table 1 Baseline Characteristics for Participants With Echocardiography
Levothyroxine Placebo
n = 96 n = 89
Demographics*
Age (y, mean § SD) 74.4 § 5.3 73.8 § 5.9
Female (n, %) 44 (45.8) 43 (48.3)
White (n, %) 95 (99.0) 87 (97.8)
Cardiovascular risk factors
BMI (kg/m2, mean § SD)y 27.6 § 4.9 26.9 § 4.7
Blood pressure (mm Hg, mean § SD)
Systolic 138.6 § 18.0 139.1 § 20.0
Diastolic 74.3 § 10.9 77.4 § 12.9
Currently smoking (n, %)z 8 (8.3) 9 (10.1)
Diabetes mellitus (n, %) 14 (14.6) 6 (6.7)
Preexisting CVD (n, %)x 28 (25.7) 32 (29.6)
Preexisting HF (n, %) 1 (1.0) 5 (5.6)
Estimated creatinine clearance (n, %){
Normal (≥90 mL/min) 5 (5.2) 6 (6.7)
Mild (60-89 mL/min) 53 (55.2) 58 (65.2)
Moderate (30-59 mL/min) 35 (36.5) 22 (24.7)
Severe (< 30 mL/min) 3 (3.1) 3 (3.4)
History of atrial fibrillation (n, %) 14 (14.6) 9 (10.1)
Lipid profile
Total cholesterol (mmol/L, mean § SD)** 5.11 § 1.11 5.31 § 1.10
LDL cholesterol (mmol/L, mean § SD)yy 2.88 § 1.01 2.98 § 0.94
HDL cholesterol (mmol/L, mean § SD)zz 1.46 § 0.48 1.51 § 0.46
Triglycerides (mmol/L, mean § SD)xx 1.78 § 1.14 1.79 § 0.91
Concomitant medication
Antiplatelets (n, %) 30 (31.3) 27 (30.3)
Lipid-lowering (n, %) 44 (45.9) 32 (36.0)
Statin (n, %) 43 (44.8) 32 (36.0)
Antihypertensives (n, %) 58 (60.4) 47 (52.8)
Diuretics (n, %) 16 (16.7) 9 (10.1)
ACE inhibitor/ARB (n, %) 45 (46.9) 35 (39.3)
Beta-blockers (n, %) 29 (30.2) 20 (22.5)
Antidiabetics (n, %) 14 (14.6) 4 (4.5)
Insulin (n, %) 4 (4.2) 1 (1.1)
Cardiac function
NT-pro BNP (pg/mL; median, IQR){{ 148 (158) 101 (114)
Baseline thyroid function
TSH (mIU/L, mean § SD) 6.26 § 1.75 6.47 § 2.17
FT4 (pmol/L, mean § SD) 13.6 § 2.0 13.7 § 1.8
ACE = angiotensin-converting enzyme; ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker; BMI = body mass index; CKD-
EPI = chronic kidney disease epidemiology collaboration; CVD = cardiovascular disease; FT4 = free thyroxine; HDL = high-density lipoprotein; HF = heart
failure; IQR = interquartile range; LDL = low-density lipoprotein; n = number; NT-pro BNP = N-terminal pro b-type natriuretic peptide; SD = standard devia-
tion; TSH = thyroid-stimulating hormone; y = years.
*Baseline characteristics of all participants (n = 217) are provided in Supplemental Table 2, available online.
yCalculated as weight (kg) divided by squared height (m).
zDefined as currently smoking at the time of baseline examination.
xDefined as 1 or more of the following: acute coronary syndrome (myocardial infarction, stable or unstable angina), coronary or other arterial revascu-
larization, stroke, transient ischemic attack, peripheral arterial disease.
{Calculated using the CKD-EPI equation.
**Missing for 2 participants in the placebo group.
yyCalculated using the Friedewald equation if triglycerides were lower than 4.6 mmol/L (400 mg/dL). Missing for 4 participants in the levothyroxine
group and 4 participants in the placebo group.
zzMissing for 1 participant in the levothyroxine group and 3 participants in the placebo group.
xxMissing for 2 participants in the placebo group.
{{Missing for 5 participants in the placebo group and 3 participants in the levothyroxine group.
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Table 2 Outcomes for Echocardiographic Systolic and Diastolic Cardiac Functions
Levothyroxine Placebo Difference* P Value
N Mean (SD) N Mean (SD) Mean (95% CI)
Systolic Function
Left ventricular ejection fraction (%)y 95 62.9 (7.9) 89 62.5 (7.4) 0.4 (1.8 to 2.5) 0.72
Global longitudinal strain (%) 58 17.8 (3.5) 58 18.5 (3.7) 0.5 (0.8 to 1.8) 0.43
Diastolic Function
E/e’ 85 10.6 (3.7) 84 10.1 (3.3) 0.4 (0.7 to 1.4) 0.47
e’ lateral (cm/s) 77 7.8 (1.8) 76 8.1 (2.5) 0.2 (0.9 to 0.5) 0.54
e’ septal (cm/s) 86 5.8 (1.3) 85 5.9 (1.9) 0.1 (0.6 to 0.4) 0.75
Left atrial volume index (mL/m2) 90 34.7 (15.9) 85 32.9 (11.7) 1.2 (3.0 to 5.5) 0.57
Systolic pulmonary artery pressure (mm Hg) 62 36.6 (12.2) 51 32.5 (10.0) 5.1 (0.9 to 9.2) 0.02
E/A ratio 81 0.8 (0.3) 81 0.8 (0.2) 0.00 (0.1 to 0.1) 0.94
E deceleration time (ms) 78 225.5 (56.8) 78 216.22 (53.3) 9.7 (7.5 to 26.9) 0.27
CI = confidence interval; n = number; SD = standard deviation.
*Calculated using multivariable linear regression adjusted for sex, center, treatment starting dose, and length of follow-up.
yThe range (min-max) of the left ventricular ejection fraction was 38%-80% in the levothyroxine arm and 20%-77% in the placebo arm.Missing values
for primary and secondary endpoints: 1 participant had not measurable left ventricular ejection fraction. A total of 16 participants (11 in the levothyr-
oxine group and 5 in the placebo group) had E/e’ outcomes not measurable with the recorded examinations. The systolic pulmonary artery pressure
was not measurable in 72 participants (34 in the levothyroxine group and 38 in the placebo group). A total of 10 participants had not measurable left
atrial volume (6 in the levothyroxine group and 4 in the placebo group). Global longitudinal strain was performed only if the quality of images allowed
to perform speckle tracking.
852 The American Journal of Medicine, Vol 133, No 7, July 2020died (2 of them from cardiovascular causes) as did 1 in the
placebo group (Supplemental Table 1, available online).
This resulted in a modified intention-to-treat population of
96 in the intervention group and 89 in the control group.
Missing data for the primary echocardiographic outcome
were equally distributed between the randomized arms
(P = 0.61 for left ventricular ejection fraction and P = 0.55
for E/e0).
Baseline characteristics were well balanced except for a
higher prevalence of diabetes in the intervention group
(Table 1 and Supplemental Table 2, available online). The
median time from baseline until echocardiography exami-
nation was 18.4 months (interquartile range 12.2-30.4) in
the levothyroxine group and 18.2 months (interquartile
range 12.2-24.7) in the placebo group.Thyroid Function Tests
At 6 to 8 weeks after randomization, TSH decreased to 2.95
§ 1.08 (range 0.9-5.4) mIU/L in the levothyroxine group
and to 5.37 § 2.04 (range 1.9-12.6) mIU/L in the placebo
group (P <0.001). At 12 months, the mean TSH was 3.48
§ 2.12 mIU/L in the levothyroxine group and 5.25 §
2.23 mIU/L in the placebo group (adjusted between-group
difference 1.74 mIU/L, P <0.001; Supplemental Figure 1,
available online). There was no patient with a TSH between
0.4 and 0.6 mIUL/L at 12 months in both arms, whereas 2
participants had a TSH <0.4 mIU/L at 12 months in the lev-
othyroxine arm.Systolic and Diastolic Cardiac Function
The mean left ventricular ejection was 62.7% § 7.9 in the
levothyroxine group and 62.5% § 7.4 in the placebo group
(adjusted between-group difference 0.4%, 95% confidenceinterval [CI] -1.8% to 2.5%, P = 0.72, Table 2). The range
(min-max) of the left ventricular ejection fraction was
38%-80% in the levothyroxine arm and 20%-77% in the
placebo arm. Regarding diastolic function, no statistically
significant differences were found for the E/e0 ratio (10.6 vs
10.1, adjusted between-group difference 0.4, 95%CI -0.7 to
1.4, P = 0.47). For secondary outcomes, no significant dif-
ferences were observed in longitudinal systolic function
(-17.8% § 3.5 vs -18.5% § 3.7, adjusted between-group
difference 0.5%, 95% CI -0.8% to 1.8%, P = 0.43). Regard-
ing diastolic function, no statistically significant differences
were found for E wave, lateral and septal e0, E/A ratio, E-
wave deceleration time, left atrial volume indexed (all P
>0.25), except for systolic pulmonary artery pressure
(37 mm Hg in the levothyroxine group vs 33 mm Hg in the
placebo group, P = 0.02 in intention-to-treat, but P = 0.06 in
per protocol, Supplemental Table 3, available online). In sen-
sitivity analyses, results were similar after excluding 16
patients with atrial fibrillation or nonsinus rhythm at the time
of examination (Supplemental Table 4, available online).
There was no significant difference between treatment groups
in heart rate at the time of echocardiography (P = 0.69). The
proportions of patients with normal systolic function (93.7%
vs 97.8%, P = 0.24) and according to diastolic function clas-
sification (normal function 54.3% vs 58.1%, indeterminate
16.1% vs 16.3% and diastolic dysfunction 29.6% vs 25.6%,
P = 0.57) were similar in the levothyroxine group and the
placebo group (Table 3).
Prespecified stratification for primary endpoints according
to sex, baseline TSH level, or history of prior cardiovascular
disease or heart failure, as well as post hoc stratification
according to baseline use of antihypertensive medication and
treatment duration did not reveal any statistically significant
differences among subgroups in favor of levothyroxine
Table 3 Classification of Echocardiographic Cardiac Function
Abnormalities
Levothyroxine Placebo P Value*
N (%) N (%)
Ejection fraction 95 89 0.24
Normal (%) 89 (93.7) 87 (97.8)
Reduced (defined as ≤50%) 6 (6.3) 2 (2.3)
Diastolic dysfunction in
patients with normal LVEF
81 86 0.57
Normal function (%) 44 (54.3) 50 (58.1)
Indeterminate (%) 13 (16.1) 14 (16.3)
Diastolic dysfunction (%) 24 (29.6) 22 (25.6)
*Calculated using logistic or ordinal logistic regression models,
adjusting for sex, center, treatment starting dose, and length of fol-
low-up.
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atory sensitivity analyses excluding participants with diabetes
mellitus (Supplemental Table 5, available online) and adjust-
ing for presence of diabetes mellitus (Supplemental Table 6,
available online) did not show statistically significant
between-group differences. Similar findings were observed
when excluding the 9 participants who had a baseline TSH
≥10 mIU/L (Supplemental Table 7, available online) or
excluding those with preexisting heart failure (Supplemental
Table 8, available online). The assessment of cardiovascularTable 4 Stratified Analyses for Echocardiographic Systolic Function
LVEF Levothyroxine P
n Mean § SD n
LVEF (% § SD) 95 62.7 § 7.9 89
Stratified by sex
Male 52 61.3 § 8.8 46
Female 43 64.3 § 6.2 43
Stratified by baseline TSH
4.6-6.9 mIU/L 73 62.6 § 7.6 67
7.0-9.9 mIU/L 18 63.2 § 9.3 17
≥10 mIU/L 4 66.3 § 6.0 5
Stratified by prior CVDy
Yes 23 60.1 § 8.5 20
No 72 63.5 § 7.5 69
Stratified by use of antihypertensive
medicationz
Yes 57 61.6 § 8.8 47
No 38 64.3 § 6.0 42
Stratified by treatment duration
< median (18.4 months) 45 62.2 § 7.5 46
≥ median (18.4 months) 50 63.2 § 8.2 43
CI = confidence interval; CVD = cardiovascular disease; LVEF = left ventricular e
ulating hormone.
Analyses were adjusted for stratification variables (sex, study center, starting
ified analyses, an interaction term between the stratification variable and the tre
*Calculated using multivariable linear regression adjusted for sex, center, tre
term for each stratification variable with treatment allocation
yDefined as at least 1 of the following: acute coronary syndrome (myocardial
larization, heart failure, stroke, transient ischemic attack, peripheral arterial di
zDefined as use of angiotensin-converting enzyme II inhibitor, angiotensin rrisk factors (blood pressure and cholesterol), biomarkers
(high-sensitivity C-reactive protein [hs-CRP] and NT-
proBNP) and cardiovascular medication at baseline and after
12 months did not show any significant differences over time
in the levothyroxine and placebo groups (Supplemental Table
9, available online). At baseline, the median NT-proBNP lev-
els were slightly higher in the group randomized to levothyr-
oxine compared with placebo (156 vs 110 pg/mL, P = 0.014),
but between-group changes over time were not statistically
significant (38 pg/mL, 95% CI14 to 91, P = 0.15).DISCUSSION
In this double-blind randomized placebo-controlled trial of
185 participants older than 65 years with mild subclinical
hypothyroidism, systolic and diastolic cardiac function did
not differ after treatment of levothyroxine compared to pla-
cebo after a median follow-up of 18.4 months.
Although the measurement of TSH is recommended in the
assessment and management of heart failure,18 few studies
have assessed the impact of thyroid hormone therapy on car-
diac function in patients with subclinical hypothyroidism.19
The available evidence was from young adults with mild
subclinical hypothyroidism and moderate-sized studies.9-11
In a nonrandomized study of 26 subjects (mean age 32.6 years
old) with subclinical hypothyroidism and 30 controls,
echo-Doppler parameters of diastolic dysfunction werelacebo Between-group
difference, 95% CI*
P Value P for
interactionMean § SD
62.5 § 7.4 0.4 (1.8 to 2.5) 0.72
63 § 6.0 0.7 (3.7 to 2.2) 0.62 0.27
62 § 8.7 1.7 (1.5 to 4.8) 0.30
62.9 § 8.0 0.1 (2.5 to 2.4) 0.96 0.71
61.4 § 5.8 1.6 (3.4 to 6.5) 0.53
61.6 § 4.3 3.3 (6.6 to 13.2) 0.51
59.2 § 10.5 1.6 (2.8 to 6.1) 0.47 0.51
63.5 § 6.0 0.0 (2.4 to 2.4) 0.98
62.0 § 8.4 0.3 (2.5 to 3.2) 0.24 0.86
63.1 § 6.1 0.7 (2.5 to 4.0) 0.44
62.6 § 8.6 0.3 (2.7 to 3.4) 0.84 0.96
62.5 § 6.0 0.4 (2.6 to 3.5) 0.79
jection fraction; n = number; SD = standard deviation; TSH = thyroid-stim-
dose of Levothyroxine) and time to visit, using linear regression. For strat-
atment group was added.
atment starting dose, and length of follow-up and including an interaction
infarction, stable or unstable angina), coronary or other arterial revascu-
sease.
eceptor blocker, beta-blocker, or diuretic at baseline.
Table 5 Stratified Analyses for Echocardiographic Diastolic Function
E/e’ (ratio § SD) Levothyroxine Placebo Between-group
difference, 95% CI*
P Value P for
interaction
N Mean § SD N Mean § SD
E/e’ (ratio § SD) 85 10.6 § 3.7 84 10.1 § 3.3 0.4 (0.7 to 1.4) 0.47
Stratified by sex
Male 47 10.7 § 3.6 42 10.1 § 2.7 0.7 (0.8 to 2.1) 0.37 0.60
Female 38 10.4 § 3.9 42 10.2 § 3.9 0.1 (1.5 to 1.7) 0.91
Stratified by baseline TSH
4.6-6.9 mIU/L 65 10.4 § 3.3 62 10.2 § 3.3 0.2 (1.0 to 1.4) 0.72 0.86
7.0-9.9 mIU/L 16 11.4 § 4.8 17 10.4 § 3.7 0.9 (1.5 to 3.3) 0.47
≥10 mIU/L 4 9.8 § 5.7 5 8.0 § 1.0 1.0 (3.7 to 6.0) 0.67
Stratified by prior CVD/HFy
Yes 21 12.2 § 3.3 17 11.2 § 3.6 1.0 (1.3 to 3.2) 0.41 0.57
No 64 10.1 § 3.7 67 9.8 § 3.2 0.2 (1.0 to 1.4) 0.72
Stratified by use of antihypertensive
medicationz
Yes 48 11.4 § 4.0 42 11.0 § 2.9 0.3 (1.2 to 1.7) 0.69 0.93
No 37 9.6 § 2.9 42 9.2 § 3.5 0.4 (1.2 to 2.0) 0.63
Stratified by treatment duration
< median (18.4 months) 41 10.6 § 3.6 43 9.6 § 3.5 1.1 (0.4 to 2.6) 0.15 0.19
≥ median (18.4 months) 44 10.5 § 3.8 41 10.7 § 3.0 0.3 (1.8 to 1.2) 0.69
CI = confidence interval; CVD = cardiovascular disease; E/e’ = ratio between mitral peak velocity of early filling (E) to early diastolic mitral annular veloc-
ity (e’); HF = heart failure; n = number; SD = standard deviation; TSH = thyroid-stimulating hormone.
Analyses were adjusted for stratification variables (sex, study center, starting dose of Levothyroxine) and time to visit, using linear regression. For strat-
ified analyses, an interaction term between the stratification variable and the treatment group was added.
*Calculated using multivariable linear regression adjusted for sex, center, treatment starting dose, and length of follow-up and including an interaction
term for each stratification variable with treatment allocation.
yDefined as at least 1 of the following: acute coronary syndrome (myocardial infarction, stable or unstable angina), coronary or other arterial revascu-
larization, heart failure, stroke, transient ischemic attack, peripheral arterial disease.
zDefined as use of angiotensin-converting enzyme II inhibitor, angiotensin- receptor blocker, beta-blocker, or diuretic at baseline.
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isovolumetric relaxation time, increased A wave, and
reduced E/A ratio.10 Thyroid hormone replacement of sub-
clinical hypothyroidism was associated with a shortening of
isovolumetric relaxation time, a reduction of the A wave, and
an increase of the E/A ratio.10 Among 20 patients with sub-
clinical hypothyroidism, those randomized to levothyroxine
compared to placebo presented changes in diastolic dysfunc-
tion (reduction of peak A and isovolumetric relaxation
time).9 Regarding the effect of levothyroxine in patients with
heart failure, a retrospective cohort study reported an
increased risk of cardiovascular death and major adverse car-
diovascular events with thyroxine therapy.20
Our findings suggest that treating subclinical hypothyroid-
ism with levothyroxine had no effect on systolic and diastolic
cardiac function. The only difference was observed for a sec-
ondary endpoint of diastolic function with slightly higher val-
ues of systolic pulmonary pressure in the levothyroxine group.
The reason of this finding could be an error type I because the
P value was not significant in per protocol analysis. Subjects
allocated to the levothyroxine might have been at higher risk
of heart failure by chance, as suggested by higher NT-pro
BNP levels, in the levothyroxine group compared to placebo
group at the 2 different time points (at baseline and at 12-
month follow-up). However, the lack of between-group differ-
ences in cardiovascular risk factors, NT-pro BNP levels, andother biomarkers and cardiovascular treatments at 12 months
after adjustment for baseline values rather supported that thy-
roid replacement had no effect on heart function after a
median follow-up of 18.4 months in patients with subclinical
hypothyroidism. Our data confirm the statement of the 2019
clinical practice recommendation that concluded that most
adults with subclinical hypothyroidism would not benefit from
treatment with thyroid hormones.21
Our study also has some limitations. First, because of the
low number of older patients with TSH ≥10 mIU/L (n = 9),
our study findings are mainly applicable to patients with
mild hypothyroidism. No significant effect modification of
levothyroxine was observed by baseline prespecified TSH
levels, and the overall results did not change after excluding
those with TSH ≥10 mIU/L (Supplemental Table 7, avail-
able online), but we could not address with appropriate
power the effect of levothyroxine in those with more pro-
nounced subclinical hypothyroidism. The proportion of
older participants with TSH ≥10 mIU/L in our study was
representative of the reality because the prevalence of such
abnormality at this age category accounts only for about
5% of the patients with subclinical hypothyroidism.22 Sec-
ond, we designed the TRUST trial in 201123, so we chose
to set a thyrotropin target of 0.40 to 4.60 mIU/L with levo-
thyroxine treatment, which was the usual approach at this
time24 and the range used to define euthyroidism in the
Gencer et al TRUST-Echocardiography 855Thyroid Studies Collaboration.25 The 2013 European Thy-
roid Association guidelines have even recommended a
lower thyrotropin target (eg, 0.40-2.50 mIU/L),12 although
a higher TSH target between 1 and 5 mIU/L may be consid-
ered for adults >70 years of age,12 as well as the use of age-
specific reference range for the diagnosis of subclinical
hypothyroidism in the elderly.22,26 The latest guidelines
from the American Thyroid Association also recommended
to raise the target serum TSH in older adults.27 Third, we
did not have available measurement for triiodothyronine
(T3), which has been previously associated with diastolic
function.28 Fourth, we did not have baseline echocardiogra-
phy. In randomized design, baseline participant characteris-
tics (including unmeasured confounding factors) should be
evenly distributed, and the addition of the primary outcome
measurement at the end of the trial is a frequent design in
imaging studies 15,16 and in other RCTs.29,30 Our data sug-
gest that the studied population had likely no major under-
lying systolic heart failure at enrolment (no baseline
echocardiography) because 93.7% in the levothyroxine arm
and 97.8% in the placebo arm had a normal ejection frac-
tion at the end of the trial. Therefore, our study does not
preclude a beneficial or detrimental effect of thyroxine
replacement in individuals with preexisting echocardio-
graphic abnormalities. Finally, the ethnic diversity of the
study population was limited (white race was 99.0% in the
levothyroxine arm and 97.8% in the placebo arm).
Our trial has several strengths. The sample size was
larger than those of previous trials of thyroid replacement
and cardiac function.9,10 In the absence of any previous or
ongoing adequately powered RCT regarding major cardio-
vascular outcomes, this study is the largest RCT to date
assessing the effect of thyroid hormone therapy in subclini-
cal hypothyroidism using recommended surrogate out-
comes of heart failure.CONCLUSION
Systolic and diastolic function did not differ after treatment
with levothyroxine compared to placebo in older adults
with mild subclinical hypothyroidism.REFERENCES
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Supplemental Table 1 Summary of Adverse Events
All Participants n = 217 Levothyroxine n = 109 Placebo n = 108
Clinical Outcome
Fatal or nonfatal cardiovascular event, n (%) 13 (6.0) 7 (6.4) 6 (5.6)
Cardiovascular death, n (%) 2 (0.9) 2 (1.8) 0 (0.0)
All-cause death, n (%) 5 (2.5) 4 (3.7) 1 (0.9)
Serious adverse event*
Participants with ≥1 serious adverse event, n (%) 65 (30%) 30 (27.5) 35 (32.4)
Number of events, n 121 54 67
Withdrawal
Permanent withdrawal from study drug, n (%) 45 (20.7) 22 (20.2) 23 (21.3)
Withdrawal from follow-up, n (%) 16 (7.4) 6 (5.5) 10 (9.3)
n = number.
*Serious adverse event was defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization
or prolongation of existing hospitalization, or resulted in persistent or significant disability/incapacity.
Supplemental Table 2 Baseline Characteristics of All Participants (N = 217)
Levothyroxine Placebo
n = 109 n = 108
Demographics*
Age (y, mean § SD) 74.5 § 5.4 74.6 § 6.2
Female (n, %) 50 (45.9) 50 (46.3)
White race (n, %) 107 (98.2) 106 (98.2)
Cardiovascular risk factors
BMI (kg/m2, mean § SD)y 27.9 § 5.3 26.9 § 4.6
Blood pressure (mm Hg, mean § SD)
Systolic 137.6 § 18.2 138.5 § 20.0
Diastolic 74.1 § 11.2 77.4 § 12.3
Currently smoking (n, %)z 8 (7.3) 10 (9.3)
Diabetes mellitus (n, %) 17 (15.6) 11 (10.2)
Prior CVD (n, %)x 26 (23.9) 30 (27.8)
Prior heart failure (n, %) 3 (2.8) 7 (6.5)
Estimated creatinine clearance (n, %){
Normal (≥90 mL/min) 7 (6.4) 6 (5.6)
Mild (60- <90 mL/min) 61 (56.0) 70 (64.8)
Moderate (30- <60 mL/min) 38 (34.9) 28 (25.9)
Severe (<30 mL/min) 3 (2.8) 4 (3.7)
History of atrial fibrillation (n, %) 16 (14.7) 13 (12.0)
Lipid profile
Total cholesterol (mmol/L, mean § SD)** 5.08 § 1.09 5.18 § 1.11
LDL cholesterol (mmol/L, mean § SD)yy 2.84 § 0.99 2.88 § 0.93
HDL cholesterol (mmol/L, mean § SD)zz 1.44 § 0.47 1.49 § 0.46
Triglycerides (mmol/L, mean § SD)xx 1.80 § 1.13 1.78 § 0.87
Concomitant medication
Antiplatelets (n, %) 33 (30.3) 36 (33.3)
Lipid-lowering (n, %) 49 (45.0) 42 (38.9)
Statin (n, %) 47 (43.2) 41 (38.0)
Antihypertensives (n, %) 70 (64.2) 59 (54.6)
Diuretics (n, %) 21 (19.3) 12 (11.1)
ACEII/ARB (n, %) 55 (50.5) 43 (39.8)
Beta-blockers (n, %) 32 (29.4) 26 (24.1)
Antidiabetics (n, %) 17 (15.6) 8 (7.4)
Insulin (n, %) 5 (4.6) 1 (0.9)
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Supplemental Table 2 (Continued)
Levothyroxine Placebo
n = 109 n = 108
Cardiac function
NT-pro BNP (pg/mL; median, IQR){{ 156 (175) 110 (144)
Thyroid function
TSH (mIU/L, mean § SD) 6.40 § 2.02 6.51 § 2.12
FT4 (pmol/L, mean § SD) 13.5 § 2.0 13.7 § 1.9
ACEII = angiotensin-converting enzyme II; ARB = angiotensin-receptor blocker; BMI = body mass index; CKD-EPI = chronic kidney disease epidemiology
collaboration; CVD = cardiovascular disease; FT4 = free thyroxine; HDL = high-density lipoprotein; IQR = interquartile range; LDL = low-density lipoprotein;
n = number; NT-pro BNP = N-terminal pro b-type natriuretic peptide; SD = standard deviation; TSH = thyroid-stimulating hormone; y = years.
*Baseline characteristics of participants in the primary analysis (n = 186) are provided in the Table 1.
yCalculated as weight (kg) divided by squared height (m)
zDefined as currently smoking at the time of baseline examination.
xDefined as 1 or more of the following: acute coronary syndrome (myocardial infarction, stable or unstable angina), coronary or other arterial revascu-
larization, stroke, transient ischemic attack, peripheral arterial disease
{Calculated using the CKD-EPI equation.
**Missing for 2 participants in the placebo group.
yyCalculated using the Friedewald equation if triglycerides lower than 4.6 mmol/L. Missing for 4 participants in the levothyroxine group and 4 partici-
pants in the placebo group.
zzMissing for 1 participant in the levothyroxine group and 3 participants in the placebo group.
xxMissing for 2 participants in the placebo group.
{{Missing for 5 participants in the placebo group and 3 participants in the levothyroxine group.
Supplemental Figure 1 Distribution of the TSH at 12 months (mIU/L) in the placebo (red) and
in the treatment arm (blue). TSH = thyroid-stimulating hormone.
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Supplemental Table 5 Outcomes for Echocardiographic Systolic and Diastolic Cardiac Functions After Excluding Patients With Diabetes
Levothyroxine Placebo Difference* P Value
N Mean (SD) N Mean (SD) Mean (95% CI)
Systolic Function
Left ventricular ejection fraction (%) 81 63.7 § 7.0 83 62.3 § 7.5 1.3 (0.8 to 3.5) 0.23
Global longitudinal strain (%) 50 18.2 § 3.2 50 18.5 § 3.7 0.1 (1.3 t0 1.4) 0.93
Diastolic Function
E/e’ 72 10.5 § 3.8 81 10.1 § 3.4 0.4 (0.8 to 1.5) 0.53
e’ lateral (cm/s) 64 8.0 § 1.7 73 8.1 § 2.5 0.1 (0.8 to 0.7) 0.86
e’ septal (cm/s) 73 5.9 § 1.2 81 6.0 § 1.9 0.0 (0.6 to 0.5) 0.87
Left atrial volume index (mL/m2) 77 34.5 § 16.9 79 32.7 § 14.0 1.0 (3.7 to 5.7) 0.67
Systolic pulmonary artery pressure (mm Hg) 56 37.0 § 12.7 39 30.9 § 7.2 6.9 (2.9 to 10.9) 0.001
Maximal tricuspid regurgitation velocity (cm/s) 40 261.8 § 38.3 29 241.4 § 25.5 22.6 (7.5 to 37.7) 0.004
E/A ratio 69 0.9 § 0.3 73 0.82 § 0.21 0.03 (0.05 to 0.11) 0.49
E deceleration time (ms) 68 223.4 § 57.6 68 215.9 § 52.6 7.6 (10.5 to 25.6) 0.41
CI = confidence interval; n = number; SD = standard deviation.
*Calculated using multivariable linear regression adjusted for sex, center, treatment starting dose, and length of follow-up.
Supplemental Table 3 Per Protocol Analysis for Outcomes for Echocardiographic Systolic and Diastolic Cardiac Functions
Levothyroxine Placebo Difference* P Value
N Mean § SD N Mean § SD Mean (95% CI)
Left ventricular ejection fraction (%) 80 62.5 § 8.0 81 62.8 § 7.6 0.2 (2.1 to 2.6) 0.84
E/e’ 71 10.5 § 3.8 76 9.9 § 3.0 0.5 (0.6 to 1.6) 0.39
Systolic Pulmonary artery pressure (mm Hg) 54 36.7 § 12.9 44 33.3 § 10.4 4.5 (0.2 to 9.3) 0.06
CI = confidence interval; n = number; SD = standard deviation.
*Calculated using multivariable linear regression adjusted for sex, center, treatment starting dose, and length of follow-up.
Supplemental Table 4 Outcomes for Echocardiographic Systolic and Diastolic Cardiac Functions After Excluding Patients With Atrial
Fibrillation
Levothyroxine Placebo Difference* P Value
N Mean (SD) N Mean (SD) Mean (95% CI)
Systolic Function
Left ventricular ejection fraction (%) 74 64.0 § 6.3 74 63.2 § 5.6 0.7 (1.2 to 2.5) 0.46
Global longitudinal strain (%) 48 18.5 § 3.0 50 19.0 § 3.2 0.5 (0.8 to 1.8) 0.46
Diastolic Function
E/e’ 71 10.2 § 3.6 73 9.9 § 3.4 0.2 (0.9 to 1.3) 0.72
e’ lateral (cm/s) 63 7.9 § 1.7 68 8.1 § 2.6 0.2 (0.9 to 0.6) 0.63
e’ septal (cm/s) 71 5.9 § 1.2 74 5.9 § 2.0 0.0 (0.5 to 0.6) 0.89
Left atrial volume index (mL/m2) 72 31.7 § 11.3 71 30.6 § 9.9 1.1 (2.4 to 4.5) 0.54
Systolic pulmonary artery pressure (mm Hg) 48 34.7 § 10.0 39 29.9 § 5.7 5.4 (1.8 to 9.0) 0.003
Maximal tricuspid regurgitation velocity (cm/s) 36 259.7 § 39.9 29 240.7 § 27.5 22.6 (5.1 to 40.2) 0.01
E/A ratio 72 0.81 § 0.25 73 0.81 § 0.22 0.0 (0.1 to 0.1) 0.99
E deceleration time (ms) 71 219.9 § 53.0 68 216.5 § 55.2 3.8 (14.2 to 21.8) 0.68
CI = confidence interval; n = number; SD = standard deviation.
*Calculated using multivariable linear regression adjusted for sex, center, treatment starting dose, and length of follow-up.
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Supplemental Table 6 Outcomes for Echocardiographic Systolic and Diastolic Cardiac Functions After Adjusting For Diabetes
Levothyroxine Placebo Difference* P Value
N Mean (SD) N Mean (SD) Mean (95% CI)
Systolic Function
Left ventricular ejection fraction (%) 95 62.7 § 7.7 83 62.5 § 7.4 0.6 (1.5 to 2.8) 0.55
Global longitudinal strain (%) 58 17.8 § 3.5 58 18.5 § 3.7 0.2 (1.1 to 1.5) 0.76
Diastolic Function
E/e’ 85 10.6 § 3.7 84 10.1 § 3.3 0.4 (0.7 to 1.5) 0.49
e’ lateral (cm/s) 77 7.8 § 1.8 76 8.1 § 2.5 0.1 (0.8 to 0.6) 0.83
e’ septal (cm/s) 86 5.8 § 1.3 85 5.9 § 1.9 0.0 (0.5 to 0.5) 0.87
Left atrial volume index (ml/m2) 90 34.7 § 15.9 85 32.9 § 11.7 1.1 (3.2 to 5.4) 0.62
Systolic pulmonary artery pressure (mm Hg) 62 36.6 § 12.2 51 32.5 § 10.0 4.9 (0.8 to 9.0) 0.02
Maximal tricuspid regurgitation velocity (cm/s) 43 262.2 § 38.1 38 246.6 § 34.7 18.2 (2.7 to 33.7) 0.02
E/A ratio 81 0.8 § 0.3 81 0.82 § 0.22 0.02 (0.06 to 0.09) 0.65
E deceleration time (ms) 78 225.5 § 56.8 78 216.2 § 53.3 8.7 (8.7 to 26.1) 0.33
CI = confidence interval; n = number; SD = standard deviation.
*Calculated using multivariable linear regression adjusted for sex, center, treatment starting dose, and length of follow-up.
Supplemental Table 8 Outcomes for Echocardiographic Systolic and Diastolic Cardiac Functions After Excluding Those Preexisting Heart
Failure
Levothyroxine Placebo Difference* P Value
N Mean (SD) N Mean (SD) Mean (95% CI)
Systolic Function
Left ventricular ejection fraction (%) 94 62.8 § 7.8 84 63.1 § 6.0 0.0 (2.0 to 2.0) 0.98
Global longitudinal strain (%) 57 17.8 § 3.5 55 18.8 § 3.4 0.6 (0.7 to 2.) 0.34
Diastolic Function
E/e’ 84 10.6 § 3.7 80 10.0 § 3.3 0.5 (0.6 to 1.5) 0.41
e’ lateral (cm/s) 76 7.8 § 1.8 72 8.1 § 2.5 0.3 (1.0 to 0.4) 0.46
e’ septal (cm/s) 85 5.8 § 1.3 81 5.9 § 2.0 0.1 (0.6 to 0.4) 0.73
Left atrial volume index (ml/m2) 89 34.4 § 15.7 82 31.7 § 10.7 2.2 (1.7 to 6.1) 0.26
Systolic pulmonary artery pressure (mm Hg) 61 36.3 § 12.1 48 31.7 § 9.2 5.1 (1.1 to 9.2) 0.01
Maximal tricuspid regurgitation velocity (cm/s) 43 262.2 § 38.1 36 245.0 § 34.9 19.7 (3.2 to 36.2) 0.02
E/A ratio 81 0.83 § 0.27 79 0.82 § 0.22 0.00 (0.08 to 0.07) 0.94
E deceleration time (ms) 78 225.5 § 56.8 75 215.3 § 53.4 10.3 (7.1 to 27.7) 0.25
CI = confidence interval; n = number; SD = standard deviation.
*Calculated using multivariable linear regression adjusted for sex, center, treatment starting dose, and length of follow-up.
Supplemental Table 7 Outcomes for echocardiographic systolic and diastolic Cardiac Functions After Excluding Those With a Baseline
TSH ≥10 mUI/L
Levothyroxine Placebo Difference* P Value
N Mean (SD) N Mean (SD) Mean (95% CI)
Systolic Function
Left ventricular ejection fraction (%) 91 62.5 § 7.9 84 62.6 § 7.6 0.3 (2.0 to 2.5) 0.82
Global longitudinal strain (%) 54 17.8 § 3.5 53 18.4 § 3.8 0.4 (0.9 to 1.8) 0.53
Diastolic Function
E/e’ 81 10.6 § 3.6 79 10.3 § 3.4 0.4 (0.7 to 1.4) 0.53
e’ lateral (cm/s) 73 7.8 § 1.8 71 8.0 § 2.5 0.1 (0.8 to 0.6) 0.73
e’ septal (cm/s) 82 5.8 § 1.3 80 5.9 § 1.9 0.1 (0.6 to 0.5) 0.83
Left atrial volume index (ml/m2) 86 34.8 § 16.2 80 32.7 § 14.0 1.9 (2.5 to 6.3) 0.40
Systolic pulmonary artery pressure (mm Hg) 59 36.9 § 12.4 50 32.6 § 10.0 5.4 (1.2 to 9.6) 0.01
Maximal tricuspid regurgitation velocity (cm/s) 41 263.2 § 38.6 37 247.2 § 34.9 20.3 (3.5 to 37.2) 0.02
E/A ratio 77 0.8 § 2.7 76 0.8 § 0.22 0.02 (0.06 to 0.10) 0.64
E deceleration time (ms) 74 219.9 § 51.7 73 218.0 § 54.0 3.2 (14.0 to 20.) 0.72
CI = confidence interval; n = number; SD = standard deviation; TSH = thyroid-stimulating hormone.
*Calculated using multivariable linear regression adjusted for sex, center, treatment starting dose, and length of follow-up.
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Supplemental Table 9 Control of Cardiovascular Risk Factors, Biomarkers, and Medication From Baseline to 12-months Follow-Up
Baseline Follow-Up Difference P Value
Levothyroxine Placebo Levothyroxine Placebo (95% CI)
Cardiovascular risk factors*
Systolic blood pressure (mm Hg, mean § SD)y 137.8 § 18.2 139.0 § 19.9 134.8 § 18.4 134.8 § 16.9 0.6 (3.3 to 4.5) 0.76
Diastolic blood pressure (mm Hg, mean § SD)z 74.1 § 11.2 77.6 § 12.4 73.1 § 10.9 75.1 § 11.6 0.2 (2.8 to 2.5) 0.89
LDL cholesterol (mmol/L, mean § SD)x,{ 2.85 § 1.00 2.90 § 0.95 2.67 § 0.95 2.74 § 0.98 0.02 (0.19 to 0.15) 0.82
Inflammation marker
High-sensitivity CRP (mg/L, mean § SD)** 2.31 § 1.69 2.50 § 2.05 2.30 § 1.77 2.35 § 1.85 0.06 (0.36 to 0.48) 0.78
Cardiac function
NT-proBNP (pg/mL, median § IQR)yy 156 (175) 110 (144) 201 (252) 118 (146) 38 (14 to 91) 0.15
Medicationszz
Antiplatelets (n, %) 31 (32.0) 34 (37.4) 30 (30.9) 37 (40.7) 0.04 (0.08 to 0.00) 0.04
Lipid-lowering (n, %) 46 (47.4) 37 (40.7) 47 (48.5) 39 (42.9) 0.01 (0.07 to 0.04) 0.68
Statin (n, %) 45 (46.4) 36 (39.6) 46 (47.4) 38 (41.8) 0.01 (0.07 to 0.04) 0.68
Antihypertensives (n, %) 64 (66.0) 54 (59.3) 63 (65.0) 55 (60.4) 0.02 (0.08 to 0.04) 0.48
Antidiabetics (n, %) 16 (16.6) 7 (7.7) 16 (16.5) 8 (8.8) 0.01 (0.05 to 0.02) 0.55
Insulin (n, %) 5 (5.2) 1 (1.1) 5 (5.2) 1 (1.1) — 1.00
CI = confidence interval; CRP = C-reactive protein; LDL = low-density lipoprotein; n = number; NT-pro BNP = N-terminal pro b-type natriuretic peptide; SD = standard deviation.
*Analyses conducted in the modified intention-to-treat population (all correctly randomized participants with the respective outcome available). Results are adjusted for stratification variables (sex, treat-
ment starting dose, study center) and baseline level of the same variable using linear regression. Between-group difference is the value in the levothyroxine group minus the value in the placebo group.
yN = 202 Missing in placebo|levothyroxine group: 0|0 at baseline, 8|7 at 12 months.
zN = 202. Missing in placebo|levothyroxine group: 0|0 at baseline, 8|7 at 12 months.
xN = 191. Missing in placebo|levothyroxine group: 4|4 at baseline, 12|9 at 12 months.
{Sensitivity analysis excluding participants on lipid-lowering medications (statins, fibrates; n = 89) yielded similar results.
**N = 183. Missing in placebo|levothyroxine group: 5|3 at baseline, 14|15 at 12 months.
yyN = 190. Missing in placebo|levothyroxine group: 5|3 at baseline, 11|11 at 12 months.
zzComplete (baseline and 12-month follow-up) medication information was unavailable for 29 participants. Data shown is for complete case (n = 188). Between-group difference (levothyroxine compared to
placebo) in change of proportions of participants using a medication were calculated using generalized estimating equation models, with an interaction term for treatment group and time.
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